---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008811"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:37:10.923573+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023

## Summary
- Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.
- Net loss for Q1 2023 was $28.3M, compared to $23.0M in Q1 2022, with R&D expenses rising to $22.8M from $16.0M.
- Company plans to initiate pivotal Phase 3 monotherapy trial of OP-1250 in second-line metastatic breast cancer in H2 2023.
- Interim Phase 2 results of OP-1250 plus palbociclib to be presented at ESMO Breast Cancer on May 12, 2023.
- Non-GAAP R&D expenses were $19.7M (excl. $3.1M SBC) vs $12.9M YoY; includes $2.8M restructuring charge.

## SEC filing metadata
- accession: 0001558370-23-008811
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/0001558370-23-008811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/olma-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008811
- JSON: https://secwatch.observer/filing/0001558370-23-008811.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008811.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: net income $28.3 million.
  - Period: first quarter ended March 31, 2023
  - Net income: $28.3 million
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023, was $28.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/0001558370-23-008811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.